The product was not returned for evaluation.From the information provided, there is no indication that there was any device malfunction, nonconformance, or misuse that contributed to the reported event.Potential adverse events in the labeling with the penumbra smart coil system include, but are not limited to, hematoma or hemorrhage at access site of entry, peripheral thromboembolic events, vessel spasm, thrombosis, dissection or perforation, thromboembolic episodes, including death.The product lot number was not provided, therefore, the manufacturing records could not be reviewed.
|
The patient was undergoing a coil embolization procedure to treat a ruptured bifurcation aneurysm in the anterior cerebral artery (aca)-anterior communicating artery (acom) using penumbra smart coils (smart coil) and a non-penumbra microcatheter.During the procedure, a smart coil would not advance into the microcatheter; therefore, the smart coil was removed.The physician then successfully placed four smart coils in the target location using the microcatheter.Afterwards, a control angiographic series was performed that indicated that there was a thrombus adjacent to a protruded loop towards a2 and small repletion defects in relation to thromboembolism in the callosomarginal artery.Subsequently, 15 ml of tirofiban intraarterial (ia) and 17 ml intravenous (iv) was administered to the patient, achieving resolution of the repletion defect.The thromboembolism was reported to be a serious adverse event with a probable relationship to the smart coil system and the index procedure.
|